Ismail Abdillahi Iltireh1, Robleh Hassan Farah2, Carlo Astini3, Median Said4, Christiane Osman Glele5 and Divya Dhananjay Singh1*
1Associate Surgeon, Department of General Surgery, Hospital Military Djibouti, Soudan
2Associate Surgeon of the Hospital Cheikho the Balballa, Djibouti, Soudan
3Visiting Surgeon, Department of General Surgery, Hospital Military Djibouti, Soudan
4Senior Consultant Anaesthesia, Department of Anaesthesia, Hospital Military Djibouti, Soudan
5Resident Anaesthetist, Department of Anaesthesia, Hospital Military Djibouti, Soudan
*Corresponding Author: Divya Dhananjay Singh, Associate Surgeon, Department of General Surgery, Hospital Military Djibouti.
Received: July 08, 2020; Published: August 12, 2020
Insulinoma is primarily a pancreatic neuroendocrine tumour, known to be rare and benign, in 90% of cases, while 10% cases are developed in Multiple Endocrine Neoplasia patients. The age of onset is 50 years, except for the malignant forms related to the MEN syndrome cases, where it appears between 20 and 40 years of age. The clinical findings and blood chemistry parameters coupled with the imaging techniques (Echo-endoscopy, CT, MRI) make it possible to locate the tumour in 80% of cases. The treatment of choice is essentially surgical, such as enucleation or removal of part of the pancreas.
Keywords: Pancreas; Hypoglycemia; Endocrine Tumour; Neuroendocrine Tumour
Citation: Ismail Abdillahi Iltireh., et al. “Pancreatic Insulinoma - The Once in a Blue Moon Oncological Episode". Acta Scientific Clinical Case Reports 1.8 (2020): 03-07.
Copyright: © 2020 Ismail Abdillahi Iltireh., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.